glp-1 obesity drug news today september 15 2025 anti-obesity drugs lead to substantial weight loss in the “real world” New Daily GLP-1 Weight Loss
Description
Mol Metab (2019) 30:72130
Cardio alone won't preserve muscleyou specifically need resistance training
Although AOM liraglutide (Saxenda) has been approved for treatment of obesity in adolescents since late 2020 ( 5 ), the approval of AOM semaglutide (Wegovy) in December 2022 for treatment of obesity for adolescents prompted new excitement ( 6 )
Now is the time to recognize and respond to addiction to ultra-processed foods
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
